Climb Bio, Inc.

For the period ended Dec 31, 2025. Filed Mar 5, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 5, 2026

CLYM$11.01+7.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$35,685	$87,229
Short-term marketable securities	65,395	63,690
Prepaid expenses and other current assets	4,769	3,953
Total current assets	105,849	154,872
Long-term marketable securities	59,572	61,610
Operating lease right-of-use assets	505	490
Property and equipment, net	288	199
Other long-term assets	1,530	16
Total assets	$167,744	$217,187
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$2,269	$705
Accrued expenses and other current liabilities	4,459	4,069
Operating lease liabilities	256	157
Total current liabilities	6,984	4,931
Operating lease liabilities, net of current portion	285	375
Total liabilities	7,269	5,306
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock, $0.0001 par value; 250,000,000 shares authorized; 47,766,338 and 67,255,434 shares issued and outstanding at December 31, 2025 and 2024, respectively	5	7
Additional paid-in capital	449,762	441,727
Accumulated other comprehensive income	435	23
Accumulated deficit	(289,727)	(229,876)
Total stockholders’ equity	160,475	211,881
Total liabilities and stockholders’ equity	$167,744	$217,187

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.